STOCK TITAN

Relay Therapeutics (RLAY) DEF 14A Filings

RLAY NASDAQ

Here are the DEF 14A proxy statements from Relay Therapeutics, Inc. (RLAY) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow RLAY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RLAY filings page.

Rhea-AI Summary

Relay Therapeutics is asking stockholders to vote at its virtual 2026 annual meeting on June 9, 2026. Key items include electing two Class III directors, an advisory approval of named executive officer pay, and ratifying Ernst & Young LLP as independent auditor for 2026.

The board is also seeking approval to amend the certificate of incorporation to increase authorized common stock from 300,000,000 to 450,000,000 shares. Stockholders of record as of April 13, 2026 may vote online, by phone, by mail, or during the webcast. The board recommends voting "FOR" all four proposals.